NI201100130A - Derivados de pirimidin indol para el tratamiento de cáncer. - Google Patents

Derivados de pirimidin indol para el tratamiento de cáncer.

Info

Publication number
NI201100130A
NI201100130A NI201100130A NI201100130A NI201100130A NI 201100130 A NI201100130 A NI 201100130A NI 201100130 A NI201100130 A NI 201100130A NI 201100130 A NI201100130 A NI 201100130A NI 201100130 A NI201100130 A NI 201100130A
Authority
NI
Nicaragua
Prior art keywords
cancer
treatment
pirimidin
indole derivatives
therapy
Prior art date
Application number
NI201100130A
Other languages
English (en)
Inventor
Michael Foote Kevin
Wilhelmus Maria Nissink Johannes
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NI201100130A publication Critical patent/NI201100130A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Abstract

Se proporcionan compuestos de pirimidinil indol de Fórmula (I), o sales farmacéuticamente aceptables de los mismos, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia, particularmente para el tratamiento de cáncer.
NI201100130A 2008-12-22 2011-06-22 Derivados de pirimidin indol para el tratamiento de cáncer. NI201100130A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13968108P 2008-12-22 2008-12-22

Publications (1)

Publication Number Publication Date
NI201100130A true NI201100130A (es) 2012-03-19

Family

ID=41682867

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201100130A NI201100130A (es) 2008-12-22 2011-06-22 Derivados de pirimidin indol para el tratamiento de cáncer.

Country Status (25)

Country Link
US (1) US20110053923A1 (es)
EP (1) EP2379530A1 (es)
JP (1) JP2012513388A (es)
KR (1) KR20110094342A (es)
CN (1) CN102325764A (es)
AR (1) AR074876A1 (es)
AU (1) AU2009332745A1 (es)
BR (1) BRPI0922475A2 (es)
CA (1) CA2750841A1 (es)
CL (1) CL2011001536A1 (es)
CO (1) CO6390107A2 (es)
CR (1) CR20110349A (es)
CU (1) CU20110137A7 (es)
DO (1) DOP2011000203A (es)
EA (1) EA201100971A1 (es)
EC (1) ECSP11011156A (es)
IL (1) IL213470A0 (es)
MX (1) MX2011006754A (es)
NI (1) NI201100130A (es)
PE (1) PE20110894A1 (es)
SG (1) SG171975A1 (es)
TW (1) TW201028410A (es)
UY (1) UY32351A (es)
WO (1) WO2010073034A1 (es)
ZA (1) ZA201105395B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101745331B1 (ko) 2008-12-19 2017-06-09 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 피라진 유도체
NZ603477A (en) 2010-05-12 2014-09-26 Vertex Pharma Compounds useful as inhibitors of atr kinase
US9334244B2 (en) 2010-05-12 2016-05-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
SA111320519B1 (ar) * 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
ES2899880T3 (es) 2011-09-30 2022-03-15 Vertex Pharma Tratamiento de cáncer de páncreas y cáncer de pulmón de células no pequeñas con inhibidores de ATR
HUE046429T2 (hu) 2011-09-30 2020-03-30 Vertex Pharma ATR kináz inhibítoraként használható vegyületek elõállítására szolgáló eljárás
IN2014KN02410A (es) 2012-04-05 2015-05-01 Vertex Pharma
EP2904406B1 (en) 2012-10-04 2018-03-21 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
JP6936007B2 (ja) 2014-06-17 2021-09-15 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｃｈｋ１阻害剤とａｔｒ阻害剤との組み合わせを使用してがんを処置する方法
TWI656121B (zh) * 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
CA2977764C (en) 2015-02-27 2021-11-09 Nantbioscience, Inc. Pyrimidine derivatives as kinase inhibitors and their therapeutical applications
MX2018003657A (es) 2015-09-30 2018-04-30 Vertex Pharma Metodo para tratar cancer usando una combinacion de agentes que dañan el adn e inhibidores de proteina relacionada con ataxia telangiectasia y rad3 (atr).
WO2017123588A1 (en) 2016-01-11 2017-07-20 Merrimack Pharmaceuticals, Inc. Inhibiting ataxia telangiectasia and rad3-related protein (atr)
AR110995A1 (es) 2017-02-24 2019-05-22 Bayer Ag Combinación de inhibidores de quinasa atr con sal de radio-223
JOP20190197A1 (ar) 2017-02-24 2019-08-22 Bayer Pharma AG مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر
CA3054247A1 (en) * 2017-02-24 2018-08-30 Antje Margret Wengner Combination of atr kinase inhibitors with parp inhibitors
WO2018153972A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combination of atr kinase inhibitors and antiandrogens
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
US10421765B2 (en) 2017-05-26 2019-09-24 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase
PT3651768T (pt) 2017-07-13 2024-03-20 Univ Texas Inibidores heterocíclicos da atr cinase
US11690911B2 (en) 2017-08-04 2023-07-04 Bayer Aktiengesellschaft Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors
EP3668839B1 (en) * 2017-08-17 2023-04-12 Board of Regents, The University of Texas System Heterocyclic inhibitors of atr kinase
WO2019110586A1 (en) 2017-12-08 2019-06-13 Bayer Aktiengesellschaft Predictive markers for atr kinase inhibitors
JP7290651B2 (ja) 2018-02-07 2023-06-13 ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド Ａｔｒ阻害剤及びその応用
EP3765008B1 (en) 2018-03-16 2023-06-07 Board of Regents, The University of Texas System Heterocyclic inhibitors of atr kinase
ES2954572T3 (es) 2018-09-07 2023-11-23 Merck Patent Gmbh Derivados de 5-morfolin-4-il-pirazolo[4,3-b]piridina
CA3116230A1 (en) 2018-10-16 2020-04-23 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
CN111606889B (zh) * 2019-02-25 2023-03-07 上海翰森生物医药科技有限公司 4-(1-环丙基-1h-吲哚-3-基)-n-苯基嘧啶-2-胺衍生物的制备方法
KR20220008869A (ko) 2019-05-14 2022-01-21 누베이션 바이오 인크. 항암 핵 호르몬 수용체-표적화 화합물
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2021098811A1 (zh) * 2019-11-21 2021-05-27 江苏恒瑞医药股份有限公司 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用
US11834458B2 (en) 2021-03-23 2023-12-05 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837529T2 (de) 1997-02-12 2007-07-26 Electrophoretics Ltd., Cobham Proteinmarker für lungenkrebs und deren verwendung
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EP1154774B1 (en) 1999-02-10 2005-06-22 AstraZeneca AB Quinazoline derivatives as angiogenesis inhibitors
SK287401B6 (sk) 1999-11-05 2010-09-07 Astrazeneca Ab Deriváty chinazolínu, spôsob ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie
NZ520640A (en) 2000-02-15 2005-04-29 Upjohn Co Pyrrole substituted 2-indolinone protein kinase inhibitors
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
SK52003A3 (en) 2000-07-07 2003-07-01 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, method for their preparation and pharmaceutical composition comprising the same
AU6623301A (en) 2000-07-07 2002-01-21 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
ATE340784T1 (de) * 2000-11-10 2006-10-15 Hoffmann La Roche Pyrimidinderivate und deren verwendung als neuropeptid-y-rezeptorliganden
DE10232572A1 (de) 2002-07-18 2004-02-05 Bayer Ag Neue 2,5-disubstituierte Pyrimidinderivate
US7772271B2 (en) * 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
KR20080052630A (ko) * 2005-09-01 2008-06-11 어레이 바이오파마 인크. Ｒａｆ 억제제 화합물 및 그의 사용 방법
JP2009523161A (ja) 2006-01-11 2009-06-18 アストラゼネカ アクチボラグ モルホリノピリミジン誘導体と療法におけるその使用
KR101435231B1 (ko) 2006-08-24 2014-10-02 아스트라제네카 아베 증식성 질환의 치료에 유용한 모르폴리노 피리미딘 유도체
EP2057129A1 (en) 2006-08-24 2009-05-13 AstraZeneca AB Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
EP2074118A2 (en) 2007-07-09 2009-07-01 AstraZeneca AB Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
KR20100042643A (ko) * 2007-07-09 2010-04-26 아스트라제네카 아베 증식성 질환을 치료하기 위한 삼중치환된 피리미딘 유도체

Also Published As

Publication number Publication date
DOP2011000203A (es) 2011-07-15
MX2011006754A (es) 2011-07-20
CL2011001536A1 (es) 2011-10-14
ZA201105395B (en) 2012-03-28
KR20110094342A (ko) 2011-08-23
CR20110349A (es) 2011-08-05
IL213470A0 (en) 2011-07-31
EA201100971A1 (ru) 2012-01-30
CO6390107A2 (es) 2012-02-29
CA2750841A1 (en) 2010-07-01
BRPI0922475A2 (pt) 2017-06-06
JP2012513388A (ja) 2012-06-14
EP2379530A1 (en) 2011-10-26
TW201028410A (en) 2010-08-01
UY32351A (es) 2010-07-30
PE20110894A1 (es) 2012-01-18
AU2009332745A1 (en) 2011-06-30
WO2010073034A1 (en) 2010-07-01
SG171975A1 (en) 2011-07-28
US20110053923A1 (en) 2011-03-03
ECSP11011156A (es) 2011-07-29
CN102325764A (zh) 2012-01-18
CU20110137A7 (es) 2012-01-31
AR074876A1 (es) 2011-02-16

Similar Documents

Publication Publication Date Title
DOP2011000203A (es) Derivados de pirimidin indol para el tratamiento de cancer
UY32203A (es) Amino pirimidinas y su uso en terapia
NI201000003A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
NI201000004A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
ECSP10010693A (es) Compuestos pirazólicos 436
CR11641A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
NI201200184A (es) Morfolinopirimidinas y su uso en terapia
UY30759A1 (es) Compuestos quimicos
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
ECSP109935A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
UY31141A1 (es) Compuestos de piperidina y sus usos
ECSP10010664A (es) Derivados de urea heterocíclicos para el tratamiento de infecciones bacterianas
UY31865A (es) Derivados de urea heterocíclicos y métodos para la utilización de los mismos
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
UY32694A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
CR11584A (es) Derivados de oxindol sustituidos y uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina
UY32316A (es) Derivados de piperidina utiles en el tratamiento de infecciones bacterianas
UY30982A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones.
CU20100005A7 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
CU23604B7 (es) Compuestos terapéuticos
CU23596A3 (es) Derivados de pirazol-quinazolina y proceso para su preparación